

Identifying, Managing and Mitigating Therapy-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following antineoplastic agents is associated with an increased risk of ventricular tachycardia?
 - a. Ibrutinib
 - b. Obinutuzumab
 - c. Venetoclax

2. Which of the following drugs is not recommended for patients taking oral antineoplastic agents with QT-prolongation potential?
 - a. Azithromycin only
 - b. Ondansetron only
 - c. Sertraline only
 - d. Azithromycin, ondansetron and sertraline

3. Which of the following statements is correct regarding the impact of oral antineoplastic agents on QT interval and cardiac rhythm in patients with cancer?
 - a. QT prolongation is universally defined and standardized
 - b. The risk of torsades de pointes increases with increasing corrected QT interval (QTc)
 - c. Tachycardia generally does not represent sinus or a true atrial or ventricular arrhythmia

4. At what QTc threshold increase over baseline should manual measurement and Fridericia correction be completed for patients receiving oral antineoplastic agents?
 - a. >20 ms
 - b. >40 ms
 - c. >60 ms
 - d. >80 ms